- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Monday, 14 November 2016
-
Current Status:
Answered by Shona Robison on 24 November 2016
To ask the Scottish Government, in light of the Scottish Medicines Consortium's decision not to recommend nivolumab for use by patients with advanced renal cell carcinoma, what options it is considering to make this treatment available.
Answer
I refer the member to the answer to question S5W-04618 on 21 November 2016. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at http://www.parliament.scot/parliamentarybusiness/28877.aspx
- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Monday, 14 November 2016
-
Current Status:
Answered by Shona Robison on 24 November 2016
To ask the Scottish Government what assessment it has made of the Scottish Medicines Consortium's decision not to recommend nivolumab for use by patients with advanced renal cell carcinoma.
Answer
I refer the member to the answer to question S5W-04618 on 21 November 2016. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at http://www.parliament.scot/parliamentarybusiness/28877.aspx
- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Wednesday, 23 November 2016
-
Current Status:
Taken in the Chamber on 1 December 2016
To ask the Scottish Government when the Minister for Transport and the Islands last met ScotRail and what issues were discussed.
Answer
Taken in the Chamber on 1 December 2016
- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Tuesday, 15 November 2016
-
Current Status:
Answered by Aileen Campbell on 23 November 2016
To ask the Scottish Government what the costs would be for introducing a gender-neutral human papillomavirus (HPV) vaccination programme.
Answer
It is not possible to know what the costs of a gender neutral HPV vaccination programme would be until the JCVI has made its final recommendation, as this will determine the eligibility group to be vaccinated, and potentially the vaccine product to be used.
Modelling work to look at the impact and cost effectiveness of such a programme is currently being undertaken by Public Health England and is expected to report in early 2017. Following this, and once all the necessary evidence is available, the JCVI will begin its deliberations on extending the HPV vaccination programme to adolescent boys.
The Scottish Government will of course carefully consider any future recommendations made by the JCVI on HPV vaccination.
- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Tuesday, 15 November 2016
-
Current Status:
Answered by Aileen Campbell on 23 November 2016
To ask the Scottish Government for what reason the national treatment target for the hepatitis C virus (HCV) remained the same for 2016-17 when the cost of HCV medicines has reportdly reduced due to savings made in the tendering process.
Answer
The treatment target is based on advice from the Treatment and Therapies sub-group. This group includes representatives from Health Protection Scotland, NHS Boards, National Procurement and patient representatives. Targets for 2016-17 were considered at a point when the treatment landscape was developing rapidly and during a period of high treatment demand. The group felt that in this context maintaining the target for a further year would provide the most stability to NHS Boards, but that the target should reviewed again for 2017-18. The national treatment target is a minimum target only and treatment numbers in 2016-17 are currently forecast to be 1871. This compares with 1724 treatments in 2015-16.
- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Tuesday, 15 November 2016
-
Current Status:
Answered by Aileen Campbell on 23 November 2016
To ask the Scottish Government when it expects to be in a position to implement a human papillomavirus (HPV) vaccination programme for boys.
Answer
I refer the member to the answer to question S5W-04716 on 23 November 2016. All answers to written parliamentary questions are available on the Parliament's website, the search for which can be found at: http://www.parliament.scot/parliamentarybusiness/28877.aspx.
- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Tuesday, 15 November 2016
-
Current Status:
Answered by Aileen Campbell on 23 November 2016
To ask the Scottish Government for what reason some NHS boards are treating people who have the hepatitis C virus according to national treatment targets while others are treating within a medicine budget.
Answer
NHS Boards are responsible for the clinical care of their local population and for making decisions on the use of their allocated budgets. It is for NHS Boards to assess the needs of their local population and deliver services accordingly. In the case of hepatitis C the incidence and prevalence of the disease varies across Scotland as does the distribution of genotypes of the disease. This means the scale and nature of hepatitis C infection in different Boards can necessitate a different response. The treatment target set by Scottish Government is a national target, and this target that has been met or exceeded each year.
- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Tuesday, 15 November 2016
-
Current Status:
Answered by Aileen Campbell on 23 November 2016
To ask the Scottish Government what estimates it has made of the likely impact of providing the quadrivalent human papillomavirus (HPV) vaccine to boys as well as girls.
Answer
The Scottish Government is advised on all vaccination matters by the Joint Committee on Vaccination and Immunisation (JCVI).
The JCVI recognises the importance of ongoing assessment of HPV vaccination for boys and agreed that further work was required to consider the vaccination of adolescent boys against HPV. Modelling work to look at the impact and cost effectiveness of such a programme is currently being undertaken by Public Health England and is expected to report in early 2017. Following this, and once all the necessary evidence is available, the JCVI will begin its deliberations on extending the HPV vaccination programme to adolescent boys.
The Scottish Government will of course carefully consider any future recommendations made by the JCVI on HPV vaccination.
- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Tuesday, 15 November 2016
-
Current Status:
Answered by Aileen Campbell on 23 November 2016
To ask the Scottish Government what action it is taking to ensure that NHS boards optimise the savings from discounted medicines to treat more people who have the hepatitis C virus.
Answer
The national treatment target is a minimum target and is based on reducing hepatitis C related serious liver disease and working towards the eradication of hepatitis C as a serious public health concern within Scotland. NHS Boards are responsible for ensuring that they optimise treatment availability for their local population within their local budgets.
- Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
-
Date lodged: Monday, 24 October 2016
-
Current Status:
Answered by Aileen Campbell on 10 November 2016
To ask the Scottish Government how much funding it has provided to tackle childhood obesity levels and for maintaining healthy child weight in each of the last five years, also broken down by NHS Board.
Answer
The Scottish Government has provided the following funding to NHS Boards for tackling childhood obesity and child healthy weight since 2012-13.
NHS Board
|
2012-13 allocation
£
|
2013-14 allocation
£
|
2014-15 allocation
£
|
2015-16 allocation
£
|
NHS Ayrshire and Arran
|
147,281
|
147,000
|
142,750
|
139,790
|
NHS Borders
|
59,273
|
59,000
|
58,127
|
57,591
|
NHS Dumfries and Galloway
|
74,705
|
74,000
|
72,257
|
71,084
|
NHS Fife
|
138,684
|
138,000
|
131,603
|
129,477
|
NHS Forth Valley
|
115,581
|
115,000
|
110,565
|
109,247
|
NHS Grampian
|
181,460
|
181,000
|
178,389
|
176,815
|
NHS Greater Glasgow and Clyde
|
427,116
|
427,000
|
381,390
|
370,003
|
NHS Highland
|
129,259
|
129,00
|
126,893
|
125,092
|
NHS Lanarkshire
|
206,325
|
206,000
|
219,837
|
217,119
|
NHS Lothian
|
266,113
|
266,000
|
250,458
|
248,158
|
NHS Orkney
|
32,005
|
32,000
|
32,963
|
32,542
|
NHS Shetland
|
32,396
|
32,000
|
32,563
|
32,5471
|
NHS Tayside
|
154,369
|
154,000
|
146,361
|
143,988
|
NHS Western Isles
|
35,434
|
35,000
|
35,990
|
35,623
|
Total
|
2,000,001
|
1,995,000
|
1,919,849
|
1,889,000
|
The 2016-17 Budget introduced an Outcomes Framework, a single source of funding to NHS Boards for a number of strategic priorities such as prevention and reducing inequalities. It amalgamates a number of individual funding allocations into a single allocation with a value of £161.2 million across all NHS Boards. Funding for child healthy weigh is included in the Outcomes Framework. NHS Boards have the flexibility to meet agreed outcomes within the overall framework value with individual programmes losing their financial identity.